Create account

Coverage dated September 4, 2026 to September 9, 2026

Doctors stunned after promising heart drug fails major study

Headline from MLive, on the newest of 2 developments

A Novartis heart drug lowered lipoprotein(a), a genetic heart risk factor, but failed to reduce heart attacks, strokes or cardiovascular deaths.

MLive's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Developments in this update

2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.

  1. STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study

    Headline from STAT ·

  2. Newest

    Doctors stunned after promising heart drug fails major study

    Headline from MLive ·

1 report not tied to one development ·

Read the reports

Reports & sources

10 articles, oldest first.

  1. Bloomberg

    Novartis Drug Fails Key Test of New Approach to Heart Disease (opens Bloomberg)

    Published

    Bloomberg's feed description

    A Novartis AG drug billed as a potential blockbuster failed to reduce the risk of heart attacks and strokes in a final-stage trial, marking a major setback for a new approach to prevent cardiovascular disease.

  2. STAT

    STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study (opens STAT)

    Published

    STAT's feed description

    A closely watched cardiovascular drug from Novartis failed in a pivotal study, the company said Friday, a major blow to the firm.

  3. Investor's Business Daily

    Novartis, Ionis Tumble On Surprise Flop For Heart Drug (opens Investor's Business Daily)

    Published

    Investor's Business Daily's feed description

    Novartis said late Friday its Ionis-partnered Lp(a) blocker failed in testing. The results sent Novartis and Ionis stocks tumbling.

  4. Bloomberg

    Novartis Heart-Drug Flop Deepens Pipeline Setbacks, Hits Rivals (opens Bloomberg)

    Published

    Bloomberg's feed description

    Novartis AG suffered a second trial disappointment within a week after the Swiss pharma group’s potential blockbuster heart drug failed in a final-stage study.

  5. MLive

    Doctors stunned after promising heart drug fails major study (opens MLive)

    Published

    MLive's feed description

    A Novartis heart drug lowered lipoprotein(a), a genetic heart risk factor, but failed to reduce heart attacks, strokes or cardiovascular deaths.

  6. Bloomberg

    Novartis Heart Drug Failure Rattles Market for Rival Treatments (opens Bloomberg)

    Published

    Bloomberg's feed description

    Few new ideas in heart-drug research appeared to have as much going for them as Lp(a).

Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.

Doctors stunned after promising heart drug fails major study | Since Then